Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Too easy of a first question I guess but I got a little info from Marty. Very impressed with the quick responses.
Hey Marty,
Thanks for the quick response! Just had a couple of questions about AMMX..
Do you know if the plan is to get audited financials and then move up through the OTC exchanges, followed by a bigger board listing? - YES
Any idea when auditing might begin and what costs it incurs? - The costs for the initial two-year audit (including writing of the 10Ks, printing charges, etc.) range between $75-$100,000. A date to begin the audit has not been chosen.
Has management indicated any interest in share buybacks or anything of that nature when larger lump sums are infused into the company? - There has been not discussion of a buy back but of a dividend to shareholders. This could change as we progress with various projects.
Thanks so much.
So what happens when the possible profits a company will make on a 200mil $$ deal could end up being more than their total market cap? $$$? Lol
19,765 shares @ .025, someone sell to me if you don't want them any longer :)
I can't wait to see what happens when Elite announces a partnership. LOL. $1 pps easy, if not more.
But it was an .06 penny stock. LOL LOL. See the trajectory?
Yeah okay sure. LOLOL.
More than doubling the generic pipeline this year, at least 1 (or 2) ART NDA filing this year, more clinical trials and results to follow, likely a partnership in the works... Yep, plenty of catalysts like I said. LOL.
That us? Hmm, doesn't make sense.
Yes, stocks do indeed go up and down. Funny though that the absolute LOWEST point so far this year has been more than double the price the stock started out with in January. "P&Ds" fizzle out very quickly and usually return to the starting point, if not lower. We've consistently stayed higher and have been basing in the .30s and .40s areas lately, a good 3-4 times higher YTD. FACT. But hey, don't take my word for it. Check the chart yourself. LOLOL.
Major catalysts headed our way this year and everyone knows it! LOL
Share price has gone up several multiples YTD as well as since last year's .06s and that's a FACT that can't be denied. LOLOLOL!!!!!
Hahah yep!!! I have made some "nice coin" as well so far. Best is yet to come. The company has gotten MUCH less risky than when I first started investing in 2011. As my buddy likes to say, ART is coming and not a damn thing anyone can do about it!
Well what does it matter that Mehta is gone if the tech is as "bad" / "also ran" as claimed? LOL. Can't have it both ways!!!
I believe it would! Precedents have to be set somehow, don't they?
A couple of Elite's formulations have been proven to be at least BIOEQUIVALENT (equal) if not better than the branded product they were compared to. This obviously means the opioid reduces pain, just common sense if one has a decent grasp on the English language. Looking forward to 1 and maybe 2 ART filings this calendar year, cheers.
Never gets old reading those successful results PRs Lasers!! I am most excited about the abuse liability studies. Cannot wait for those results to demonstrate that our products will be extremely difficult to abuse and will therefore solidify their place in the opioid market. It is my personal opinion that if we have not gotten a partner before those abuse trial results, we will afterward. Should be a phenomenal rest of the year and beyond.
I think more attention will be paid to Camargo's opinion as an expert in the field. Thanks anyway though. NEXT.
Prove why it isn't true.
Okay. That makes sense. It is also clearly stated in the 505b2 process, efficacy data previously submitted can be re-used. So Elite uses Embeda's efficacy data. Then what? Shouldn't that suffice? That plus our data showing that the naltrexone is sufficiently sequestered should be enough. Precedence is desirable but it also isn't everything.
How could a drug be considered bioequivalent to a painkiller but not reduce pain? Does morphine reduce pain? Does Oxycodone reduce pain?
Lasers, just thinking out loud... Would it unreasonable to assume that we may cut out the Naltrexone ANDA altogether once we have 1 or 2 ART products selling in the marketplace? Seems like using it instead for our ART products would be MUCH more beneficial and would remove some of the need for Naltrexone. So we wouldn't be burning the candle at both ends, so to speak. Your thoughts?
While I think 2$ and less per share is quite low-balling it when you know what we have lined up.... That 2$/share would also land me over $800,000 in gains so.... While I think we are most definitely worth more than that, I couldn't complain much about making almost a million bucks off of one stock play. Lol. How about you, what's your magic number should a buyout be presented?
I'll stick with Elite and the USPTO over a made-up phrase. Thanks anyway.
15 ART products in the pipe, at least 1 to be filed this year and more next year!!!!! I'm pumped!!!! Wonder who we'll partner with?? Could be Actavis... Or maybe Pfizer seeing as they have had a LOT of trouble with Embeda! Maybe they should just sweep that bad idea under the rug and partner up with the guys that have the right answer - Elite Pharmaceuticals!
Doesn't matter. Precedent has been provided. Can the FDA approve a drug with up to Phase II results and that answer is YES, SO, NEXT.
I read further. Did it get approved based on the phase II or not? Answer: yes. Next.
Wonder how anything ever got approved in the first place then if there weren't any precedents to begin with when the FDA was created.
Cool, check out the breast cancer drug Avastin. Precedent for conditional approval after Phase II set. Next.
I wouldn't say had a problem "previously" until it gets back on the market and stays there. IF that ever happens. LOL
Best part about ELTP is it only takes 1 ART product to make every investor here quite a few greenbacks. And this will most likely occur next year!!! I couldn't be more excited.
Well I mean it doesn't take a rocket scientist to realize they've had significant problems with Embeda. Lol lol if they didn't, it would've remained on the market these past few years. Fact!
Good thing Elite has at least 15 working opioid/naltrexone combos in the pipe!$!$!$!$!
Agreed richme. If our ART is as good as we all (and Nasrat and co) think it is, we will have no problem with obtaining market share in the opioid space.
Yeah Doog is legit on another board/stock we are both in. He'll be a great addition to this board IMO.
Glad you were able to get a position before this run we are having! Cheers.
I will when I get off work! Think I'm still the other mod here.
Did you end up picking up some shares Doog? Best of luck to you.
I could not care less about that. I care more about Nasrat's vision for this company and the "amount of skin he has in the game" to the tune of 150+ MILLION shares. He will ensure his own and my own success concurrently with this company's abuse resistant technology. NDA filing(s) by end of year and more than doubling the generic product line and both are only months away!
Yeah sure ok LOL LOL.
Yeah busy trying to sweep Embeda under the rug I'm sure. LOL
Lol wow 4.60! Unreal! Grats guys!
Wow it IS going nuts! Woot!
So you are thinking all 15 formulations are currently being tested at Lifetree for abuse potential?
Yessir! Been here since about March 2011 myself, just read iHub for awhile before I actually joined and started posting. About 100x more excited about Elite's future than I was in 2011 too.
So I've heard .27, .26, .255, teens, even single digits coming and every single call has been wrong. LOL.
Sticking with the ELTP management and DD longs who have established a long history of credibility and truthful posts.
*****
REALLY looking forward to those abuse liability results. Do you or does anyone else have any idea how long studies like these usually take to complete / result?
Hmm. What about the teens or .20s though?
At least you notified the SEC. Cheers to that. As our price trends higher with increased revenues, products approved, more trials and results, the MMs will have less control. Best to focus on the bright future that lay ahead for Elite. Maybe try taking some profits off the table to ease your mind about it. Best of luck.